Vaccination strategies against Zika virus

Current Opinion in Virology

Volumn 23, Issue , 2017, Pages 59-67

  Fernandez, Estefania ^a   Diamond, Michael S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VACCINE; ADENOVIRUS VECTOR; DNA; EPITOPE; INACTIVATED VACCINE; INACTIVATED VIRUS VACCINE; LIVE VACCINE; MESSENGER RNA; ZIKA VIRUS VACCINE; DNA VACCINE; RECOMBINANT VACCINE; SUBUNIT VACCINE; VIRUS VACCINE;

HUMAN; HUMORAL IMMUNITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; VACCINATION; ZIKA VIRUS; ADVERSE DRUG REACTION; ANIMAL; CLINICAL TRIAL (TOPIC); DENGUE; GUILLAIN BARRE SYNDROME; IMMUNOLOGY; ISOLATION AND PURIFICATION; MOUSE; PRECLINICAL STUDY; ZIKA FEVER;

ANIMALS; CLINICAL TRIALS AS TOPIC; DENGUE; DRUG EVALUATION, PRECLINICAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GUILLAIN-BARRE SYNDROME; HUMANS; MICE; VACCINES, DNA; VACCINES, INACTIVATED; VACCINES, SUBUNIT; VACCINES, SYNTHETIC; VIRAL VACCINES; ZIKA VIRUS; ZIKA VIRUS INFECTION;

EID: 85017646438     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2017.03.006     Document Type: Review

References (98)

1. 1 Weaver, S.C., Costa, F., Garcia-Blanco, M.A., Ko, A.I., Ribeiro, G.S., Saade, G., Shi, P., Vasilakis, N., Zika virus: history, emergence, biology, and prospects for control. Antiviral Res. 130 (2016), 69–80.
2. 2 Brasil, P., Pereira Junior, J.P., Raja Gabaglia, C., Damasceno, L., Wakimoto, M., Ribeiro Nogueira, R.M., Carvalho de Sequeira, P., Machado Siqueira, A., Abreu de Carvalho, L.M., Cotrim da Cunha, D., et al. Zika virus infection in pregnant women in Rio de Janeiro—preliminary report. N. Engl. J. Med., 2016, 10.1056/NEJMoa1602412.
3. 3• Rasmussen, S.A., Jamieson, D.J., Honein, M.A., Petersen, L.R., Zika virus and birth defects—reviewing the evidence for causality. N. Engl. J. Med. 374 (2016), 1981–1987 The authors analyzed available epidemiological data to establish that fetal anomalies are caused by ZIKV infection during the first trimester.
4. 4 van der Eijk, A.A., van Genderen, P.J., Verdijk, R.M., Reusken, C.B., Mögling, R., van Kampen, J.J.A., Widagdo, W., Aron, G.I., GeurtsvanKessel, C.H., Pas, S.D., et al. Miscarriage associated with Zika virus infection. N. Engl. J. Med. 375 (2016), 1002–1004.
5. 5 Schaub, B., Vouga, M., Najioullah, F., Gueneret, M., Monthieux, A., Harte, C., Muller, F., Jolivet, E., Analysis of blood from Zika virus-infected fetuses: a prospective case series. Lancet 3099 (2017), 26–28.
6. 6 Honein, M.A., Dawson, A.L., Petersen, E.E., Jones, A.M., Lee, E.H., Yazdy, M.M., Ahmad, N., Macdonald, J., Evert, N., Bingham, A., et al. Birth defects among fetuses and infants of US women with evidence of possible Zika virus infection during pregnancy. JAMA 30333 (2016), 59–68.
7. 7 Cao-Lormeau, V.-M., Blake, A., Mons, S., Lastère, S., Roche, C., Vanhomwegen, J., Dub, T., Baudouin, L., Teissier, A., Larre, P., et al. Guillain–Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet 387 (2016), 1531–1539.
8. 8 dos Santos, T., Rodriguez, A., Almiron, M., Sanhueza, A., Ramon, P., de Oliveira, W.K., Coelho, G.E., Badaró, R., Cortez, J., Ospina, M., et al. Zika virus and the Guillain–Barró Syndrome—case series from seven countries. N. Engl. J. Med. 375 (2016), 1598–1601.
9. 9 Santana do Rosario, M., Antonio Pereira de Jesus, P., Vasilakis, N., Farias, D.S., Antônio Caires Novaes, M., Rodrigues, S.G., Martins, L.C., Fernando da Costa Vasconcelos, P., Ko, A.I., Carlos Junior Alcantara, L., et al. Case report: Guillain–Barrô Syndrome after Zika virus infection in Brazil. Am. J. Trop. Med. Hyg. 95 (2016), 1157–1160.
10. 10 Parra, B., Lizarazo, J., Jimenez- Arango, J.A., Zea- Vera, A.F., Manrique, G.G., Vargas, J., Angarita, J.A., Zuñiga, G., Gonzalez, R.L., Beltran, C.L., et al. Guillain–Barre Syndrome associated with Zika virus infection in Colombia. N. Engl. J. Med. 373 (2016), 1513–1523.
11. 11 Dick, G.W., Kitchen, S., Haddow, A., Zika virus (I): isolations and serological specificity. Trans. R. Soc. Trop. Med. Hyg. 46 (1952), 509–520.
12. 12 Dick, G.W.A., Zika virus (II): pathogenicity and physical properties. Trans. R. Soc. Trop. Med. Hyg. 46 (1952), 521–534.
13. 13 Zanluca, C., dos Santos, C.N.D., Zika virus—an overview. Microbes Infect. 18 (2016), 295–301.
14. 14 Musso, D., Nilles, E.J., Cao-Lormeau, V.-M., Rapid spread of emerging Zika virus in the Pacific area. Clin. Microbiol. Infect. 20 (2014), O595–O596.
15. 15 Campos, G., Bandeira, A., Sardi, S., Zika virus outbreak, Bahia Brazil. Emerg. Infect. Dis. 21 (2015), 1885–1886.
16. 16 Frieden, T.R., Zika virus 6 months later. JAMA 30333 (2017), 2016–2017.
17. 17 Castro, L.A., Fox, S.J., Chen, X., Liu, K., Bellan, S.E., Dimitrov, N.B., Galvani, A.P., Meyers, L.A., Real-time Zika risk assessment in the United States. bioRxiv, 2016, 10.1101/056648.
18. 18 Grard, G., Caron, M., Mombo, I.M., Nkoghe, D., Mboui Ondo, S., Jiolle, D., Fontenille, D., Paupy, C., Leroy, E.M., Zika virus in Gabon (Central Africa)—2007: a new threat from Aedes albopictus?. PLoS Negl. Trop. Dis. 8 (2014), 1–6.
19. 19 Marchette, N.J., Garcia, R., Rudnick, A., Isolation of Zika virus from Aedes aegypti: mosquitoes in Malaysia. Am. J. Trop. Med. Hyg. 18 (1969), 411–415.
20. 20 Foy, B.D., Kobylinski, K.C., Foy, J.L.C., Blitvich, B.J., da Rosa, A.T., Haddow, A.D., Lanciotti, R.S., Tesh, R.B., Probable non-vector-borne transmission of Zika virus, Colorado, USA. Emerg. Infect. Dis. 17 (2011), 880–882.
21. 21 Russell, K., Hills, S.L., Oster, A.M., Porse, C.C., Danyluk, G., Cone, M., Brooks, R., Scotland, S., Schiffman, E., Fredette, C., et al. Male-to-female sexual transmission of Zika virus—United States, January–April. Clin. Infect. Dis., 64, 2016, ciw692.
22. 22 Davidson, A., Slavinski, S., Komoto, K., Rakeman, J., Weiss, D., Suspected female-to-male sexual transmission of Zika virus—New York City, 2016. MMWR Morb. Mortal. Wkly. Rep. 65 (2016), 716–717.
23. 23 Deckard, D.T., Chung, W.M., Brooks, J.T., Smith, J.C., Woldai, S., Hennessey, M., Kwit, N., Mead, P., Male-to-male sexual transmission of Zika virus—Texas, January 2016. MMWR Morb. Mortal. Wkly. Rep. 65 (2016), 372–374.
24. 24 Gornet, M., Bracero, N., Segars, J., Zika virus in semen: what we know and what we need to know?. Semin. Reprod. Med. 34 (2016), 285–292.
25. 25 Mansuy, J.M., Dutertre, M., Mengelle, C., Fourcade, C., Marchou, B., Delobel, P., Izopet, J., Martin-Blondel, G., Zika virus: high infectious viral load in semen, a new sexually transmitted pathogen?. Lancet Infect. Dis., 16, 2016, 405.
26. 26 Murray, K.O., Gorchakov, R., Carlson, A.R., Berry, R., Lai, L., Natrajan, M., Garcia, M.N., Correa, A., Patel, S.M., Aagaard, K., et al. Prolonged detection of Zika virus in vaginal secretions and whole blood. Emerg. Infect. Dis. 23 (2017), 99–101.
27. 27 Haddow, A.D., Schuh, A.J., Yasuda, C.Y., Kasper, M.R., Heang, V., Huy, R., Guzman, H., Tesh, R.B., Weaver, S.C., Genetic characterization of Zika virus strains: geographic expansion of the Asian lineage. PLoS Negl. Trop. Dis., 6, 2012, e1477.
28. 28 Shen, S., Shi, J., Wang, J., Tang, S., Wang, H., Hu, Z., Deng, F., Phylogenetic analysis revealed the central roles of two African countries in the evolution and worldwide spread of Zika virus. Virol. Sin. 31 (2016), 118–130.
29. 29 Dowd, K.A., DeMaso, C.R., Pelc, R.S., Speer, S.D., Smith, A.R.Y., Goo, L., Platt, D.J., Mascola, J.R., Graham, B.S., Mulligan, M.J., et al. Broadly neutralizing activity of Zika virus-immune Sera identifies a single viral serotype. Nature 11 (2016), 1485–1491.
30. 30•• Dejnirattisai, W., Supasa, P., Wongwiwat, W., Rouvinski, A., Barba-spaeth, G., Duangchinda, T., Sakuntabhai, A., Malasit, P., Rey, F.A., Mongkolsapaya, J., et al. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with Zika virus. Nature Immunol. 17 (2016), 1102–1108 The authors showed that plasma from DENV-infected individuals could cross-react with and augment cellular infection of ZIKV at low concentrations. They determined this was due to antibody-dependent enhancement of infection. This study highlights the potential for ZIKV disease enhancement by cross-reactive anti-DENV antibodies.
31. 31 Priyamvada, L., Quicke, K.M., Hudson, W.H., Onlamoon, N., Sewatanon, J., Edupuganti, S., Pattanapanyasat, K., Chokephaibulkit, K., Mulligan, M.J., Wilson, P.C., et al. Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. Proc. Natl. Acad. Sci. U. S. A. 113 (2016), 7852–7857.
32. 32•• Sapparapu, G., Fernandez, E., Kose, N., Bin Cao, Fox, J.M., Bombardi, R.G., Zhao, H., Nelson, C.A., Bryan, A.L., Barnes, T., et al. Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice. Nature 540 (2016), 443–447 The authors isolated human monoclonal antibodies agains ZIKV, defined a new protective epitope at the inter-dimer interface, and showed that passive prophylaxis or therapy can protect the fetus against infection.
33. 33• Wang, Q., Yang, H., Liu, X., Dai, L., Ma, T., Qi, J., Wong, G., Peng, R., Liu, S., Li, J., et al. Molecular determinants of human neutralizing antibodies isolated from a patient infected with Zika virus. Sci. Transl. Med. 8 (2016), 1–11 The authors identified a panel of ZIKV-specific human antibodies, some of which can protect against ZIKV infection in mice. X-ray crystal structures of the antibodies with ZIKV E protein identfied three epitopes that were distinct from those reported previously for other flavivirues.
34. 34 Vogt, M.R., Moesker, B., Goudsmit, J., Jongeneelen, M., Austin, S.K., Oliphant, T., Nelson, S., Pierson, T.C., Wilschut, J., Throsby, M., et al. Human monoclonal antibodies against West Nile virus induced by natural infection neutralize at a postattachment step. J. Virol. 83 (2009), 6494–6507.
35. 35 Throsby, M., De Kruif, J., Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile Virus. J. Virol. 80 (2006), 6982–6992.
36. 36 Kimura-Kuroda, J., Yasui, K., Protection of mice against Japanese encephalitis virus by passive administration with monoclonal antibodies. J. Immunol. 141 (1988), 3606–3610.
37. 37 Mason, P.W., Dalrymple, J.M., Gentry, M.K., McCown, J.M., Hoke, C.H., Burke, D.S., Fournier, M.J., Mason, T.L., Molecular characterization of a neutralizing domain of the Japanese encephalitis virus structural glycoprotein. J. Gen. Virol. 70 (1989), 2037–2049.
38. 38 Gotuzzo, E., Yactayo, S., Córdova, E., Review article: efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years. Am. J. Trop. Med. Hyg. 89 (2013), 434–444.
39. 39 Marston, H.D., Lurie, N., Borio, L.L., Fauci, A.S., Considerations for developing a Zika virus vaccine. N. Engl. J. Med. 375 (2016), 1209–1212.
40. 40 Vogt, M.R., Dowd, K.A., Engle, M., Tesh, R.B., Johnson, S., Pierson, T.C., Diamond, M.S., Poorly neutralizing cross-reactive antibodies against the fusion loop of West Nile virus envelope protein protect in vivo via Fc receptor and complement-dependent effector mechanisms. J. Virol. 85 (2011), 11567–11580.
41. 41 Dai, L., Song, J., Lu, X., Deng, Y.-Q., Musyoki, A.M., Cheng, H., Zhang, Y., Yuan, Y., Song, H., Haywood, J., et al. Structures of the Zika Virus envelope protein and its complex with a Flavivirus broadly protective antibody. Cell Host Microbe 19 (2016), 696–704.
42. 42 Nelson, S., Jost, C.A., Xu, Q., Ess, J., Martin, J.E., Oliphant, T., Whitehead, S.S., Durbin, A.P., Graham, B.S., Diamond, M.S., et al. Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization. PLoS Pathog., 4, 2008, e1000060.
43. 43 Halstead, S.B., Mahalingam, S., Marovich, M.A., Ubol, S., Mosser, D.M., Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes. Lancet Infect. Dis. 10 (2010), 712–722.
44. 44 Crill, W.D., Roehrig, J.T., Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J. Virol. 75 (2001), 7769–7773.
45. 45 Lee, E., Lobigs, M., Substitutions at the putative receptor-binding site of an encephalitic flavivirus alter virulence and host cell tropism and reveal a role for glycosaminoglycans in entry. J. Virol. 74 (2000), 8867–8875.
46. 46 Mandl, C.W., Allison, S.L., Holzmann, H., Meixner, T., Heinz, F.X., Attenuation of tick-borne encephalitis virus by structure-based site-specific mutagenesis of a putative flavivirus receptor binding site. J. Virol. 74 (2000), 9601–9609.
47. 47 Zhao, H., Fernandez, E., Dowd, K.A., Speer, S.D., Platt, D.J., Gorman, M.J., Govero, J., Nelson, C.A., Pierson, T.C., Diamond, M.S., et al. Structural basis of Zika virus-specific antibody protection. Cell 166 (2016), 1016–1027.
48. 48 Nybakken, G.E., Oliphant, T., Johnson, S., Burke, S., Diamond, M.S., Fremont, D.H., Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature 437 (2005), 764–769.
49. 49 Dai, L., Wang, Q., Qi, J., Shi, Y., Yan, J., Gao, G.F., Molecular basis of antibody-mediated neutralization and protection against flavivirus. IUBMB Life 68 (2016), 783–791.
50. 50 Rouvinski, A., Guardado-Calvo, P., Barba-Spaeth, G., Duquerroy, S., Vaney, M.-C., Kikuti, C.M., Navarro Sanchez, M.E., Dejnirattisai, W., Wongwiwat, W., Haouz, A., et al. Recognition determinants of broadly neutralizing human antibodies against dengue viruses. Nature 520 (2015), 109–113.
51. 51 Barba-Spaeth, G., Dejnirattisai, W., Rouvinski, A., Vaney, M.-C., Medits, I., Sharma, A., Simon-Lorière, E., Sakuntabhai, A., Cao-Lormeau, V.-M., Haouz, A., et al. Structural basis of potent Zika–dengue virus antibody cross-neutralization. Nature 536 (2016), 48–53.
52. 52 Swanstrom, J.A., Plante, J.A., Plante, K.S., Young, E.F., McGowan, E., Gallichotte, E.N., Widman, D.G., Heise, M.T., de Silva, A.M., Baric, R.S., Dengue virus envelope dimer epitope monoclonal antibodies isolated from dengue patients are protective against Zika virus. MBio 7 (2016), e01123–16.
53. 53• Zhang, S., Kostyuchenko, V.A., Ng, T.-S., Lim, X.-N., Ooi, J.S.G., Lambert, S., Tan, T.Y., Widman, D.G., Shi, J., Baric, R.S., et al. Neutralization mechanism of a highly potent antibody against Zika virus. Nat. Commun., 7, 2016, 13679 The authors used cryo-electron microscopy to define structurally how EDE antibodies neutralize ZIKV, by preventing fusion of the virus to the host cell.
54. 54 Richner, J.M., Himansu, S., Dowd, K.A., Butler, S.L., Salazar, V., Fox, J.M., Julander, J.G., Tang, W.W., Shresta, S., Pierson, T.C., et al. Modified mRNA vaccines protect against Zika virus infection. Cell 168:6 (2017), 1114–1125.e.10.
55. 55 Pardi, N., Hogan, M.J., Pelc, R.S., Muramatsu, H., Andersen, H., DeMaso, C.R., Dowd, K.A., Sutherland, L.L., Scearce, R.M., Parks, R., et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature 543 (2017), 248–251.
56. 56 Abbink, P., Larocca, R.A., De La Barrera, R.A., Bricault, C.A., Moseley, E.T., Boyd, M., Kirilova, M., Li, Z., Nganga, D., Nanayakkara, O., et al. Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science (80-) 353 (2016), 1129–1132.
57. 57 Durbin, A., Vaccine development for Zika virus—timelines and strategies. Semin. Reprod. Med. 34 (2016), 299–304.
58. 58 Larocca, R.A., Abbink, P., Peron, J.P.S., Zanotto, P.M. de A., Iampietro, M.J., Badamchi-Zadeh, A., Boyd, M., Ng'ang'a, D., Kirilova, M., Nityanandam, R., et al. Vaccine protection against Zika virus from Brazil. Nature 536 (2016), 474–478.
59. 59 Muthumani, K., Griffin, B.D., Agarwal, S., Kudchodkar, S.B., Reuschel, E.L., Choi, H., Kraynyak, K.A., Duperret, E.K., Keaton, A.A., Chung, C., et al. In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine. npj Vaccines, 1, 2016, 16021.
60. 60 Routh, J., Testing of Investigational Inactivated Zika Vaccine in Human Beings. 2016, NIH news releases.
61. 61 Beckett, C.G., Tjaden, J., Burgess, T., Danko, J.R., Tamminga, C., Simmons, M., Wu, S.-J., Sun, P., Kochel, T., Raviprakash, K., et al. Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial. Vaccine 29 (2011), 960–968.
62. 62 Ferraro, B., Morrow, M.P., Hutnick, N.A., Shin, T.H., Lucke, C.E., Weiner, D.B., Clinical applications of DNA vaccines: current progress. Clin. Infect. Dis. 53 (2011), 296–302.
63. 63 Martin, J.E., Pierson, T.C., Hubka, S., Rucker, S., Gordon, I.J., Enama, M.E., Andrews, C.A., Xu, Q., Davis, B.S., Nason, M., et al. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a Phase 1 clinical trial. J. Infect. Dis. 196 (2007), 1732–1740.
64. 64 Tatsis, N., Ertl, H.C., Adenoviruses as vaccine vectors. Mol. Ther. 10 (2004), 616–629.
65. 65• Abbink, P., Maxfield, L.F., Ng'ang'a, D., Borducchi, E.N., Iampietro, M.J., Bricault, C.A., Teigler, J.E., Blackmore, S., Parenteau, L., Wagh, K., et al. Construction and evaluation of novel rhesus monkey adenovirus vaccine vectors. J. Virol. 89 (2015), 1512–1522 The authors reported a novel vaccine platform using rhesus adenoviruses as vectors that allows circumvention of immune targeting by antibodies against naturally occuring human adenoviruses.
66. 66 Dowd, K.A., Ko, S.-Y., Morabito, K.M., Yang, E.S., Pelc, R.S., DeMaso, C.R., Castilho, L.R., Abbink, P., Boyd, M., Nityanandam, R., et al. Rapid development of a DNA vaccine for Zika virus. Science (80-) 354 (2016), 237–240.
67. 67 Muthumani, K., Griffin, B.D., Agarwal, S., Kudchodkar, S.B., Reuschel, E.L., Choi, H., Kraynyak, K.A., Duperret, E.K., Keaton, A.A., Chung, C., et al. In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine. npj Vaccines, 1, 2016, 16021.
68. 68 Kim, E., Erdos, G., Huang, S., Kenniston, T., Falo, L.D., Gambotto, A., Preventative vaccines for Zika virus outbreak: preliminary evaluation. EBioMedicine 13 (2016), 315–320.
69. 69 Schlake, T., Thess, A., Fotin-Mleczek, M., Kallen, K.-J., Developing mRNA-vaccine technologies. RNA Biol. 9 (2012), 1319–1330.
70. 70 Monath, T.P., Lee, C.K., Julander, J.G., Brown, A., Beasley, D.W., Watts, D.M., Hayman, E., Guertin, P., Makowiecki, J., Crowell, J., et al. Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity. Vaccine 28 (2010), 3827–3840.
71. 71 Monath, T.P., Fowler, E., Johnson, C.T., Balser, J., Morin, M.J., Sisti, M., Trent, D.W., An inactivated cell-culture vaccine against yellow fever. N. Engl. J. Med. 364 (2011), 1326–1333.
72. 72 Heinz, F.X., Stiasny, K., Flaviviruses and flavivirus vaccines. Vaccine 30 (2012), 4301–4306.
73. 73 Tauber, E., Kollaritsch, H., Korinek, M., Rendi-Wagner, P., Jilma, B., Firbas, C., Schranz, S., Jong, E., Klingler, A., Dewasthaly, S., et al. Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial. Lancet 370 (2007), 1847–1853.
74. 74 Barrett, A.D., Teuwen, D.E., Yellow fever vaccine—how does it work and why do rare cases of serious adverse events take place?. Curr. Opin. Immunol. 21 (2009), 308–313.
75. 75 Beck, A.S., Barrett, A.D.T., Current status and future prospects of yellow fever vaccines. Expert Rev. Vaccines 14 (2015), 1479–1492.
76. 76 Bonaparte, M., Dweik, B., Feroldi, E., Meric, C., Bouckenooghe, A., Hildreth, S., Hu, B., Yoksan, S., Boaz, M., Immune response to live-attenuated Japanese encephalitis vaccine (JE-CV) neutralizes Japanese encephalitis virus isolates from south-east Asia and India. BMC Infect. Dis., 14, 2014, 156.
77. 77 Monath, T.P., McCarthy, K., Bedford, P., Johnson, C.T., Nichols, R., Yoksan, S., Marchesani, R., Knauber, M., Wells, K.H., Arroyo, J., et al. Clinical proof of principle for ChimeriVax™: recombinant live, attenuated vaccines against flavivirus infections. Vaccine 20 (2002), 1004–1018.
78. 78 Barrett, A.D., Vaccines Available Against JE. 2014, MMWR by the CDC.
79. 79 Guy, B., Jackson, N., Dengue vaccine: hypotheses to understand CYD-TDV-induced protection. Nat. Rev. Microbiol. 14 (2016), 45–54.
80. 80 Kirkpatrick, B.D., Whitehead, S.S., Pierce, K.K., Tibery, C.M., Grier, P.L., Hynes, N.A., Larsson, C.J., Sabundayo, B.P., Talaat, K.R., Janiak, A., et al. The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model study participants. Sci. Transl. Med. 8 (2016), 3–4.
81. 81 Capeding, M.R., Tran, N.H., Hadinegoro, S.R.S., Ismail, H.I.H.M., Chotpitayasunondh, T., Chua, M.N., Luong, C.Q., Rusmil, K., Wirawan, D.N., Nallusamy, R., et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 384 (2014), 1358–1365.
82. 82 Villar, L., Dayan, G.H., Arredondo-García, J.L., Rivera, D.M., Cunha, R., Deseda, C., Reynales, H., Costa, M.S., Morales-Ramírez, J.O., Carrasquilla, G., et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N. Engl. J. Med. 372 (2015), 113–123.
83. 83 Durbin, A.P., Kirkpatrick, B.D., Pierce, K.K., Carmolli, M.P., Tibery, C.M., Grier, P.L., Hynes, N., Opert, K., Jarvis, A.P., Sabundayo, B.P., et al. A 12-month–interval dosing study in adults indicates that a single dose of the National Institute of Allergy and Infectious Diseases tetravalent dengue vaccine induces a robust neutralizing antibody response. J. Infect. Dis. 214 (2016), 832–835.
84. 84 Charles, A.S., Christofferson, R.C., Utility of a dengue-derived monoclonal antibody to enhance Zika infection in vitro. PLoS Curr., 2016, 10.1371/currents.outbreaks.4ab8bc87c945eb41cd8a49e127082620.
85. 85 Kawiecki, A.B., Christofferson, R.C., Zika virus–induced antibody response enhances dengue virus serotype 2 replication in vitro. J. Infect. Dis. 214 (2016), 1357–1360.
86. 86 Paul, L.M., Carlin, E.R., Jenkins, M.M., Tan, A.L., Barcellona, C.M., Nicholson, C.O., Trautmann, L., Michael, S.F., Isern, S., Dengue virus antibodies enhance Zika virus infection. bioRxiv, 5, 2016, 50112.
87. 87(a) Stettler, K., Beltramello, M., Espinosa, D.A., Graham, V., Cassotta, A., Bianchi, S., Vanzetta, F., Minola, A., Jaconi, S., Mele, F., et al. Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. Science (80-) 353 (2016), 823–826.
88. 87(b) Bardina, S.V., Bunduc, P., Tripathi, S., Duehr, J., Frere, J.J., Brown, J.A., Nachbagauer, R., Foster, G.A., Krysztof, D., Tortorella, D., Stramer, S.L., García-Sastre Krammer, A.F., Lim, J.K., Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity. Science(March), 2017.
89. 88 Chabierski, S., Barzon, L., Papa, A., Niedrig, M., Bramson, J.L., Richner, J.M., Palù, G., Diamond, M.S., Ulbert, S., Distinguishing West Nile virus infection using a recombinant envelope protein with mutations in the conserved fusion-loop. BMC Infect. Dis. 14 (2014), 1–8.
90. 89 Hughes, H.R., Crill, W.D., Chang, G.-J.J., Manipulation of immunodominant dengue virus E protein epitopes reduces potential antibody-dependent enhancement. Virol. J., 9, 2012, 115.
91. 90 Sur, D.K., Wallis, D.H., O'Connell, T.X., Vaccinations in pregnancy. Am. Fam. Physician 68 (2003), 299–304.
92. 91 Munoz, F.M., Infant protection against influenza through maternal immunization. JAMA Pediatr., 170, 2016, 832.
93. 92 Bozzo P, Narducci A, Einarson A: Vaccination during pregnancy. 2011, 57:555–557.
94. 93 Kroger, A.T., Sumaya, C.V., Pickering, L.K., Atkinso, W.L., General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices. MMWR. Morb. Mortal. Wkly. Rep. 60 (2016), 1–60.
95. 94•• Soares de Oliveira-Szejnfeld, P., Levine, D., Melo, A.S., de, O., Amorim, M.M.R., Batista, A.G.M., Chimelli, L., Tanuri, A., Aguiar, R.S., Malinger, G., Ximenes, R., et al. Congenital brain abnormalities and Zika virus: what the radiologist can expect to see prenatally and postnatally. Radiology 281 (2016), 203–218 Radiological findings of pregnant women with confirmed ZIKV infection and their offspring before and after birth showed a range of brain abnormalities. The authors observed ventriculomegaly, cerebral calcifications, cortical migrational defects, and brainstem hypoplasia.
96. 95 Cuevas, E.L., Tong, V.T., Rozo, N., Valencia, D., Pacheco, O., Gilboa, S.M., Mercado, M., Renquist, C.M., González, M., Ailes, E.C., et al. Preliminary report of microcephaly potentially associated with Zika virus infection during pregnancy—Colombia, January–November 2016. MMWR Morb. Mortal. Wkly. Rep. 65 (2016), 1409–1413.
97. 96 van der Linden, V., Pessoa, A., Dobyns, W., Barkovich, A.J., van der L, Júnior H., Filho, E.L.R., Ribeiro, E.M., de C, Leal M., Coimbra, Coimbra P.P., de F.V.V, Aragão M., et al. Description of 13 infants born during October 2015–January 2016 with congenital Zika virus infection without microcephaly at birth—Brazil. MMWR Morb. Mortal. Wkly. Rep. 65 (2016), 1343–1348.
98. 97 Sirohi, D., Chen, Z., Sun, L., Klose, T., Pierson, T.C., Rossmann, M.G., Kuhn, R.J., The 3.8 Å resolution cryo-EM structure of Zika virus. Science 352 (2016), 467–470.